Skip to main content

Table 2 Probabilistic Sensitivity Analysis results. QALY: Quality-Adjusted Life Years, ICER: Incremental Cost-Effectiveness Ratio

From: Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry

 

Step-up

Initial Combination

Mean costs (€)

€20,163.81

€16,267.15

2.5–97.5% interval

16,588.46–23,780.33

11,534.72–21,366.87

Mean utility (QALY)

3.515

3.548

2.5–97.5% interval

2.467–4.598

2.44–4.71

ICER

–

−119,897 (Dominating)

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us